Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer
Pharmaceuticals · 08.11.2025 · 18 (11) · 1697
DOI: 10.3390/ph18111697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 08.11.2025. Verfasst von Andrea Lancia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer (PCa) is the second most common cancer in men, and it is frequently diagnosed at an advanced stage of the disease. Androgen Deprivation Therapy (ADT) has traditionally represented the backbone of therapy for high-risk, recurrent, and metastatic disease; however, in the last ten years a new group of molecules known as androgen receptor pathway inhibitors (ARPIs) have been demonstrated to improve outcomes in metastatic patients when added to ADT. Developed and validated originally in the setting of castration-resistant disease, ARPIs have been implemented progressively earlier in the natural history of PCa, involving patients who have never received ADT before or that are still responsive to this treatment. Considering the strong evidence for treatment intensification in patients with high-risk features, with this review we aim to provide a complete overview of the current indications for the use of ARPIs through all the stages of castration-sensitive prostate cancer (CSPC).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10124 Turin, Italy.
- Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, 06156 Perugia, Italy.
- Radiotherapy Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
- Radiation Oncology Unit, Azienda Unitaria Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico, 42123 Reggio Emilia, Italy.
- Radiotherapy Unit Prato, Usl Centro Toscana, Presidio Villa Fiorita, 59100 Prato, Italy.
ORCID-Profile: Andrea Lancia, Marco Oderda, Marta Bottero, Emanuele Alì, Salvatore La Mattina, Elisabetta Bonzano, David Alberto Santos Hernandez
Zitieren
APA
Lancia, A., Oderda, M., Camilli, F., Festa, E., Bottero, M., Alì, E., La Mattina, S., Bonzano, E., Saddi, J., Detti, B., Santos Hernandez, D. A., & Ingrosso, G. (2025). Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer. Pharmaceuticals, 18(11), 1697. https://doi.org/10.3390/ph18111697
Vancouver
Lancia A, Oderda M, Camilli F, Festa E, Bottero M, Alì E, et al. Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer. Pharmaceuticals. 2025;18(11):1697. doi:10.3390/ph18111697
BibTeX
@article{Lancia2025,
author = {Lancia, Andrea and Oderda, Marco and Camilli, Federico and Festa, Eleonora and Bottero, Marta and Alì, Emanuele and La Mattina, Salvatore and Bonzano, Elisabetta and Saddi, Jessica and Detti, Beatrice and Santos Hernandez, David Alberto and Ingrosso, Gianluca},
title = {Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {11},
pages = {1697},
doi = {10.3390/ph18111697}
}
EUVIMED